Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

1
Member Avatar usubanas (99.68) Submitted: 10/28/2014 9:45:26 AM : Underperform Start Price: $15.34 SRPT Score: -4.26

FDA "... concerns about the reproducibility of the data." It's going to turn ugly.

Recs

1
Member Avatar deacon (< 20) Submitted: 10/16/2014 6:50:24 PM : Outperform Start Price: $24.74 SRPT Score: -42.25

EBOLA treatment drug advanced to primate testing showing no adverse side effects

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 10/10/2014 9:35:55 PM : Outperform Start Price: $18.75 SRPT Score: -19.37

Short term burst in stock price due to Ebola panic. This stock should go higher over the next year.

Recs

1
Member Avatar jbwheels69 (47.92) Submitted: 10/1/2014 3:09:23 PM : Outperform Start Price: $21.93 SRPT Score: -30.24

Decent entry point

Recs

1
Member Avatar trizoll (51.19) Submitted: 7/16/2014 9:55:29 PM : Outperform Start Price: $20.50 SRPT Score: -23.21

Will rebound from 144 week study results. The benefit is really compared to the placebo. There is a huge benefit there. I think the drug will get approved in 2015.

Recs

0
Member Avatar MKArch (99.70) Submitted: 7/2/2014 2:30:14 AM : Outperform Start Price: $30.14 SRPT Score: -49.60

Following a guy on Yahoo Finance that sounds like he knows what he's talking about. Yep really that's it. O.K. he made an interesting argument for HART a similar company I have done a little investigating into so I'm taking a flier that he understands this one enough to put it into my CAPS portfolio. Potential multi-bagger a few years out, we shall see.

Recs

0
Member Avatar Redbeagle (35.08) Submitted: 3/17/2014 12:07:55 PM : Outperform Start Price: $27.23 SRPT Score: -49.74

Good drug pipeline

Recs

0
Member Avatar mulledover (80.04) Submitted: 3/15/2014 11:59:06 AM : Outperform Start Price: $27.38 SRPT Score: -50.49

Phase ii results in duchenne prove their capabilities although this will likely take 2-3 years for further trials. However it's their RNA platform that makes this an interesting company for antiviral drugs for infectious diseases

Recs

0
Member Avatar manirg (73.29) Submitted: 1/27/2014 12:41:25 PM : Outperform Start Price: $23.28 SRPT Score: -44.65

Its drug is only the treatment for DMD. FDA is likely to approve it sooner or later. Hugh long term potential.

Recs

0
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $24.65 SRPT Score: -47.77

The only game in town when it comes to Duchenne Muscular Dystophy.

Recs

0
Member Avatar ferrariedgardo (27.32) Submitted: 1/16/2014 6:57:41 PM : Outperform Start Price: $27.37 SRPT Score: -51.37

DMD trial going well

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $32.49 SRPT Score: +72.93

Short. Biopharma. Sells more stock than has revenues. Revs declining too.

Recs

3
Member Avatar EllenBrandtPhD (< 20) Submitted: 8/17/2013 2:58:48 PM : Outperform Start Price: $32.59 SRPT Score: -73.94

This is a terrifying stock, because its moves tend to be so dramatic.

If you calculate its next Big Turn correctly, either on the downside or the upside, you can make out like a bandit.

The technical picture could hardly have been worse prior to Friday's big up day, but there were many hints something was brewing. It came in the form of a key analyst upgrade and a new Propaganda push beginning Friday.

I think it may continue and that the next Big Turn - Propaganda leading Technicals - may be here.

Recs

3
Member Avatar TMFBiologyFool (95.77) Submitted: 7/24/2013 4:31:02 PM : Outperform Start Price: $37.00 SRPT Score: -78.00

Over punished on delay of FDA decision about surrogate endpoint. Should trend back up as we get closer to FDA decision.

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:39:26 PM : Outperform Start Price: $38.75 SRPT Score: -80.92

right drug at the right time

Recs

0
Member Avatar IBDContrarian (25.48) Submitted: 4/6/2013 1:51:34 PM : Underperform Start Price: $37.06 SRPT Score: +88.37

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 99 EB NO EARN

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:34:43 PM : Outperform Start Price: $30.37 SRPT Score: -81.47

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Recs

0
Member Avatar ravikaza2 (< 20) Submitted: 3/3/2013 7:57:45 PM : Outperform Start Price: $30.37 SRPT Score: -81.47

Only new treatment for DMD

Recs

0
Member Avatar NHWeston102 (64.56) Submitted: 2/1/2013 10:27:17 AM : Outperform Start Price: $27.48 SRPT Score: -76.58

Fast track approval, followed by pruce spike, followed by a big pharma buy out!! A good company that has done a good thing and deserves all the best - as do its buyers.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:47:23 AM : Outperform Start Price: $25.98 SRPT Score: -79.49

Will receive the first ever FDA breakthrough designation for their lead drug.

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners


Advertisement